A Phase 3 Clinical Program with the Novel Vasopressin V2 Receptor Antagonist Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Lixar (lixivaptan) - Palladio

Shusterman, Neil H; Richardson, Elaine R; Castellana, John V; Pellegrini, Lorenzo

Oct 14, 2019